Intermediate hepatocellular carcinoma: current treatments and future perspectives
- 30 April 2013
- journal article
- review article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 24 (suppl 2), 24-29
- https://doi.org/10.1093/annonc/mdt054
Abstract
Current guidelines recommend transarterial chemoembolization (TACE) as the standard treatment of Barcelona-Clinic Liver Cancer (BCLC)-B patients. However, the long-term survival outcomes of patients managed with this technique do not appear fully satisfactory; in addition, intermediate-stage hepatocellular carcinoma (HCC) includes a heterogeneous population of patients with varying tumour burdens, liver function and disease aetiology. Therefore, not all patients with intermediate-stage HCC may derive similar benefit from TACE, and some patients may benefit from other treatment options, which are currently approved or being explored. These include different TACE modalities, such as selective TACE or drug-eluting beads TACE and radioembolization. The introduction of sorafenib in the therapeutic armamentarium for HCC has provided a new therapeutic option for the treatment of BCLC-B patients who are unsuitable to TACE or in whom TACE resulted in unacceptable toxicity. In addition, clinical trials aimed at investigating the potential role of this molecule in the treatment of patients with intermediate-stage HCC within combination therapeutic regimens are ongoing. This narrative review will present and discuss the most recent evidence on the locoregional or medical treatment with sorafenib in patients with intermediate-stage HCC.Keywords
Funding Information
- Gilead Sciences
- Meso Scale Diagnostics
- Novartis
- Roche
This publication has 45 references indexed in Scilit:
- Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”Journal of Hepatology, 2012
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in ItalyHepatology, 2011
- 6500 ORAL Second Interim Results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of Its Treatment With SorafeNib) Study – Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup AnalysisEuropean Journal of Cancer, 2011
- Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomasHepatology, 2011
- Therapeutic options for intermediate-advanced hepatocellular carcinomaWorld Journal of Gastroenterology, 2011
- Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V StudyCardioVascular and Interventional Radiology, 2009
- Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients databaseHepatology, 2008
- Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402)European Journal of Cancer, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002